Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, confirms that the study’s Principal Investigator, Prof. Michel Azizi, will present phase 2a results for the drug-candidate QGC001 at the 27th European Meeting on Hypertension and Cardiovascular Protection, hosted by the European Society of Hypertension (ESH) on June 16 -19, 2017, in Milan, Italy,
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2017/05/QG-Azizi-ESH-Presentation-Announcement_09.05.2017_-VDEF-EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]